These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2505957)

  • 21. [Thyrocytes contribute to their own demise: the role of interleukin-18 in Hashimoto's thyroiditis].
    Xiao WH; Hong TP; Wang HN; Liu GQ; Liu Z; Wang YR
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(40):2817-20. PubMed ID: 19080488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin 2-activated killer cells do not mediate autologous thyrocyte lysis in autoimmune thyroid disease in vitro.
    Matsubayashi S; Akasu F; Kasuga Y; Jamieson C; Volpé R
    Thyroid; 1991; 1(2):151-6. PubMed ID: 1822361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in gene expression associated with IFN-beta and IL-2-induced augmentation of human natural killer cell function.
    Kornbluth J; Hoover RG
    J Immunol; 1988 Nov; 141(9):3234-40. PubMed ID: 3049820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic activity of NK cells against SW-756 squamous cervical carcinoma cell line: role of interferons alpha and gamma and CD54 adhesion molecule in oncolysis.
    Cristoforoni PM; Lotzová E; Cook KR; Chuang LT; Morris M; Grossi CE; Wharton JT
    Gynecol Oncol; 1994 Mar; 52(3):365-72. PubMed ID: 7512522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-gamma induces HLA-DR expression by thyroid epithelium.
    Todd I; Pujol-Borrell R; Hammond LJ; Bottazzo GF; Feldmann M
    Clin Exp Immunol; 1985 Aug; 61(2):265-73. PubMed ID: 3930110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
    Cesano A; Visonneau S; Clark SC; Santoli D
    J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
    Hogan PG; Hapel AJ; Doe WF
    J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperinducibility of HLA class II expression of thyroid follicular cells from Graves' disease. A primary defect?
    Sospedra M; Obiols G; Babi LF; Tolosa E; Vargas F; Roura-Mir C; Lucas-Martin A; Ercilla G; Pujol-Borrell R
    J Immunol; 1995 Apr; 154(8):4213-22. PubMed ID: 7706756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
    Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
    J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy in antigen presentation by thyroid epithelial cells and monocytes from patients with Graves' disease.
    Eguchi K; Otsubo T; Kawabe Y; Shimomura C; Ueki Y; Nakao H; Tezuka H; Matsunaga M; Fukuda T; Ishikawa N
    Clin Exp Immunol; 1988 Apr; 72(1):84-90. PubMed ID: 3260842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4.
    Kogure T; Fujinaga H; Niizawa A; Hai LX; Shimada Y; Ochiai H; Terasawa K
    Mediators Inflamm; 1999; 8(6):313-8. PubMed ID: 10815620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
    Utsugi T; Sone S
    J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-reactive cytotoxic gamma delta T lymphocytes in Graves' disease specifically recognize thyroid epithelial cells.
    Catálfamo M; Roura-Mir C; Sospedra M; Aparicio P; Costagliola S; Ludgate M; Pujol-Borrell R; Jaraquemada D
    J Immunol; 1996 Jan; 156(2):804-11. PubMed ID: 8543836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of human natural killer cell activity by platelet-derived growth factor. II. Membrane binding studies, effects of recombinant IFN-alpha and IL-2, and lack of effect on T cell and antibody-dependent cellular cytotoxicity.
    Gersuk GM; Chang WC; Pattengale PK
    J Immunol; 1988 Dec; 141(11):4031-8. PubMed ID: 2846698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
    Ostensen ME; Thiele DL; Lipsky PE
    J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
    Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
    J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.